Phase I study of TAK-659, an investigational, dual SYK/FLT3 iinhibitor, in patients with B-cell lymphoma
Gordon, LI Kaplan, B Popat, R Burris, HA Ferrari, S Madan, S Patel, MR Gritti, G El-Sharkawi, D Chau, I
Gordon, LI
Kaplan, B
Popat, R
Burris, HA
Ferrari, S
Madan, S
Patel, MR
Gritti, G
El-Sharkawi, D
Chau, I
Citations
Altmetric:
Abstract
Description
Date
2020
Publisher
Collections
Keywords
Type
Article
Citation
Gordon LI, Kaplan JB, Popat R, Burris HA, Ferrari S, Madan S, et al. Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-cell Lymphoma. Clin Cancer Res. 2020.